Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients (Diabetes)
|ClinicalTrials.gov Identifier: NCT01781754|
Recruitment Status : Unknown
Verified January 2013 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Recruiting
First Posted : February 1, 2013
Last Update Posted : February 1, 2013
Many patients with Diabetes find difficulties in achieving glycemic control. Hemoglobin A1c(HgBA1c) is used as a marker for glycemic control. UCP2 is affected by high glucose levels, high free fatty acids and high oxidative stress.
The investigators intend to learn about the changes in UCP2 along the process of reaching glycemic control.
|Condition or disease||Intervention/treatment|
|Diabetes||Procedure: Blood withdrawal|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Changes in UCP2 mRNA in T2DM Patients|
|Study Start Date :||January 2013|
|Estimated Primary Completion Date :||January 2014|
|Estimated Study Completion Date :||January 2014|
Un balanced diabetic patients
Procedure: Blood withdrawal
This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
- Levels of gene expression for UCP2 (RQ) [ Time Frame: 6 months ]Checking UCP2 levels compared to HgBA1c
- Improved metabolic state [ Time Frame: 6 months ]Glycemic control (glucose level and HgA1c), levels of free reactive oxygen species (ROS) and non-esterified fatty acids (NEFAs).
Biospecimen Retention: Samples Without DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01781754
|Contact: Nachum Vaisman, MDfirstname.lastname@example.org|
|Tel Aviv Sourasky Medical Center||Recruiting|
|Tel-Aviv, Israel, 64239|
|Contact: Nachum Vaisman, MD 972-3-6974807 email@example.com|
|Principal Investigator: Nachum Vaisman, MD|